Qilu Pharmaceutical Co., Ltd.

This Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than doce…

This early-stage trial tests a new drug, QLF4113, in about 140 men with metastatic castration-resistant prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and check for side effects, while also looking for si…

This Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This phase 2 trial tests an injectable drug called GM1 in 276 people with Parkinson's disease who experience motor fluctuations (times when medication wears off). Participants are randomly assigned to receive GM1 or a placebo for about 12 weeks, while continuing their usual Parki…

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…

This study compares a new oral diabetes medication, QLG1091, to the existing drug Rybelsus, both taken alongside metformin. About 478 adults with type 2 diabetes will take one of the two pills daily for 26 weeks. The goal is to see if QLG1091 controls blood sugar (HbA1c) as well …

This study tests an experimental drug called QLS1410 for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone, causing high blood pressure. The trial will compare the drug to a placebo in 60 adults to see if it safely lowers blood pres…

This Phase 1 trial tests a single injection of QLH2405 in 68 healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The main goal is to check safety and how the body processes the drug. It is too early to know if QLH2405 will help treat Alzheimer's.

This phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This phase 3 trial tests QL0911, a weekly injection, in 60 children aged 1 to 17 with chronic immune thrombocytopenia (ITP) who have low platelet counts. The goal is to see if the drug can safely raise platelet levels to reduce bleeding risk. Participants receive either QL0911 or…

This Phase 3 trial tests a new drug called QLC7401 in about 780 adults with high cholesterol that remains high despite standard therapy. Participants will receive either QLC7401 or a placebo, added to their current cholesterol medications. The main goal is to see if QLC7401 can s…

This Phase III trial tests QLC7401, a new RNA-based drug, in 120 adults with heterozygous familial hypercholesterolemia (a genetic condition causing very high cholesterol). Participants already on cholesterol medication will receive either QLC7401 or a placebo injection. The stud…

This Phase 3 trial tests a new injectable drug called QLC7401 in 510 adults with high cholesterol or mixed dyslipidemia who are not on other cholesterol treatments. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see how much it low…

This Phase II trial tests QLS12010, an oral capsule, in 102 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. The study has two parts: an open-label proof-of-concept phase and a placebo-controlled dose-ranging phase. Participants must have tr…

This study tests an experimental drug called QLS12010 in 180 adults with moderate-to-severe rheumatoid arthritis. Participants are randomly assigned to receive different doses of the drug or a placebo for 12 weeks. The main goal is to see if the drug reduces joint swelling and te…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This Phase 3 trial tests whether adding romiplostim (a platelet-boosting drug) to standard immunosuppressive therapy helps people with severe aplastic anemia achieve normal blood cell counts. About 210 participants will receive either romiplostim or a placebo alongside standard t…

This study tests whether a new drug called QL2302 works as well as the approved drug Tezspire for people with severe asthma that is not controlled by current treatments. About 636 adults aged 18-80 will receive injections every 4 weeks for 48 weeks, then be monitored for another …

This study tests a new pill called daprodustat against a standard injectable drug (darbepoetin alfa) for treating anemia in people on hemodialysis. About 100 Chinese adults will take either the pill daily or the injection weekly for 28 weeks. The goal is to see if the pill works …

This early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the …

This study tests a new drug combination (QLC5513 plus QL1706, with or without platinum chemo) in people with advanced solid tumors that have spread. The goal is to see if the treatment can shrink tumors and to check its safety. About 290 participants will take part, and the study…

This study tests a new drug called QLC1401, taken as a tablet, combined with either CDK4/6 inhibitors or mTOR inhibitors for people with ER+/HER2- advanced breast cancer. The trial has two parts: first, finding the safest dose, then checking how well it works. About 96 participan…

This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surger…

This early-stage trial will test a new drug called QLS1410 in 78 healthy adults and people with mild high blood pressure. The main goal is to check safety and how the body processes the drug. Researchers will also look at how food affects the drug and whether it lowers blood pres…

This Phase II trial tests an experimental drug called QLS31905 combined with chemotherapy, with or without another drug (QL2107), in 120 people with advanced biliary tract cancer that has a specific protein (CLDN18.2). The goal is to see if the combination shrinks tumors. Partici…

This study tests an experimental capsule called QLS12010 in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo over 16 weeks. Participants must have had eczema for at least one year…

This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.

This early-stage trial will test a new drug called QLS1410 in 12 healthy Chinese adults to see if eating affects how the body absorbs it. Participants will take the drug once with food and once without, and researchers will measure drug levels in their blood. The results will hel…

This early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…

This Phase 1 trial will compare a single dose of QL2302, a proposed biosimilar of the asthma drug Tezspire, against the original drug in 178 healthy adults aged 18 to 45. The study is double-blinded and randomized, meaning neither participants nor researchers know who gets which …

This Phase 1 trial will test the safety and tolerability of QLS7305, an investigational drug, in 60 healthy Chinese adults. Participants will receive either single or multiple doses of the drug or a placebo, along with preventive antibiotics. The study focuses on how the body pro…